Loading clinical trials...
Loading clinical trials...
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)
Conditions
Interventions
Evolocumab
Standard of care
Locations
187
United States
Research Site
Birmingham, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Tucson, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Malvern, Arkansas, United States
Research Site
Anaheim, California, United States
Start Date
October 7, 2011
Primary Completion Date
June 20, 2018
Completion Date
June 20, 2018
Last Updated
September 21, 2022
NCT07473960
NCT06568601
NCT00353782
NCT07037771
NCT07489209
NCT07058077
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions